Candel TherapeuticsCADL
CADL
About: Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
Employees: 42
0
Funds holding %
of 6,823 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 8
60% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 10
25% more capital invested
Capital invested by funds: $37.2M [Q2] → $46.4M (+$9.24M) [Q3]
16% more funds holding
Funds holding: 45 [Q2] → 52 (+7) [Q3]
0.72% more ownership
Funds ownership: 20.16% [Q2] → 20.89% (+0.72%) [Q3]
16% less call options, than puts
Call options by funds: $803K | Put options by funds: $957K
50% less funds holding in top 10
Funds holding in top 10: 2 [Q2] → 1 (-1) [Q3]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$19
185%
upside
Avg. target
$19
185%
upside
High target
$19
185%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Vernon Bernardino 37% 1-year accuracy 22 / 59 met price target | 185%upside $19 | Buy Reiterated | 18 Dec 2024 |
Financial journalist opinion
Based on 4 articles about CADL published over the past 30 days
Positive
Proactive Investors
1 week ago
Candel Therapeutics advancing lead candidate targeting prostate cancer towards FDA submission
Candel Therapeutics Inc (NASDAQ:CADL) has provided a corporate update, highlighting anticipated milestones for this year building upon significant achievements in 2024. Updated overall survival data from phase 2a trials of its lead candidate CAN-2409 in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC) are expected in the first quarter of 2025.
Neutral
GlobeNewsWire
1 week ago
Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025
NEEDHAM, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today highlighted recent successes across the Company's viral immunotherapy portfolio and provided an update on the Company's cash position and upcoming 2025 milestones.
Positive
Seeking Alpha
2 weeks ago
Best-Performing Stocks Of 2024
Taking a look at the 20 best-performing stocks in 2024 of current Russell 3,000 members.
Positive
Proactive Investors
4 weeks ago
2025 biotech outlook: Small-cap innovators tackling chronic and rare diseases
In the New Year, many small-cap biotech companies will be advancing promising clinical trials with innovative therapies aimed at addressing significant unmet medical needs. Key trials include those focused on cancer immunotherapies, treatments for neurological conditions like multiple sclerosis and Alzheimer's, as well as novel approaches to metabolic diseases and chronic pain.
Positive
Proactive Investors
1 month ago
Candel Therapeutics rides high on promising Phase 3 data, funding boost
Candel Therapeutics Inc (NASDAQ:CADL) shares skyrocketed by nearly 43% on Thursday following a string of positive news surrounding the company's cancer drug pipeline. Last week the Needham, Massachusetts-based company released promising results from its Phase 3 clinical trial for CAN-2409, its experimental immunotherapy for localized prostate cancer.
Positive
Proactive Investors
1 month ago
Candel Therapeutics raises $92M in public offering following prostate cancer trial success
Candel Therapeutics Inc (NASDAQ:CADL) announced on Monday the completion of a public offering that raised approximately $92 million in gross proceeds. The offering included 12 million shares of common stock at $6 per share and pre-funded warrants for 3.3 million shares at $5.99 per warrant, allowing buyers to acquire shares at an exercise price of $0.01 each.
Neutral
GlobeNewsWire
1 month ago
Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
NEEDHAM, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the closing of its previously announced underwritten public offering of 12,000,001 shares of its common stock at a price to the public of $6.00 per share and pre-funded warrants to purchase up to an aggregate of 3,333,333 shares of its common stock at a price to the public of $5.99 per pre-funded warrant to purchase one share of the common stock, which represents the per share public offering price for the common stock less the $0.01 per share exercise price for each such pre-funded warrant. The 12,000,001 shares of common stock sold in the offering include 2,000,000 shares sold pursuant to the full exercise of the underwriters' option to purchase up to 2,000,000 additional shares of common stock at the public offering price, less the underwriting discount.
Negative
Benzinga
1 month ago
Candel Therapeutics, 8x8 And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 150 points on Friday.
Neutral
Proactive Investors
1 month ago
Candel Therapeutics unveils $80M public offering
Candel Therapeutics Inc (NASDAQ:CADL) has announced an $80 million underwritten public offering of its common stock and pre-funded warrants. The offering includes approximately 10 million shares of common stock at $6 per share and approximately 3.33 million pre-funded warrants priced at $5.99 each, representing the public offering price minus a $0.01 per share exercise cost.
Neutral
GlobeNewsWire
1 month ago
Candel Therapeutics Announces Pricing of Public Offering
NEEDHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the pricing of an underwritten public offering of 10,000,001 shares of its common stock at a price to the public of $6.00 per share and pre-funded warrants to purchase up to an aggregate of 3,333,333 shares of its common stock at a price to the public of $5.99 per pre-funded warrant to purchase one share of the common stock, which represents the per share public offering price for the common stock less the $0.01 per share exercise price for each such pre-funded warrant. The gross proceeds from the offering to Candel are expected to be approximately $80 million, before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on or about December 16, 2024, subject to customary closing conditions. In addition, Candel has granted the underwriters a 30-day option to purchase up to 2,000,000 additional shares of common stock at the public offering price, less the underwriting discount.
Charts implemented using Lightweight Charts™